Nasdaq
$0.4990▲ 3.92%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $11.9MShares out 23.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 6d agoPre-market26.10.19 21:00S-1/AOffering#●●●#●●●#●●●
ACTUATE THERAPEUTICS, INC.Bullish
Actuate Therapeutics is conducting a public offering of 40 million shares of common stock bundled with 20 million purchase warrants. The company is also offering eligible investors the option to purchase up to 40 million pre-funded warrants in lieu of common stock, with proceeds intended to fund the clinical development of its lead drug candidate, elraglusib.…more
$0.4990+3.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 21:01S-1/AOffering
ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics is conducting a public offering of 65,000,000 shares of common stock at an assumed price of $0.6437 per share. The company has granted the underwriter a 45-day option to purchase an additional 9,750,000 shares, and major shareholders have agreed to a two-year lock-up period on their holdings following the offering.…more
$0.4990+3.92%vs prev closeView filingShare - 10.8Pre-market26.10.08 19:47FWPOther
ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics is conducting a common stock offering with Konik Capital Partners acting as the underwriter. This filing discloses the historical capital raising and fee arrangements between the participating dealer, Newbridge Securities, and the existing investor, Bios Fund III Entities.…more
$0.4990+3.92%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:58Bullish#●●●#●●●
Actuate Therapeutics Announces 50 Million Share Offering
Actuate Therapeutics plans to sell 50 million shares at an assumed price of $0.819 per share. This significant equity offering is expected to result in shareholder dilution, negatively impacting the stock.…more
$0.4990+3.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9After-hours26.09.10 06:00
●●●●●●●● ●●●●● ●●●●●●
Actuate Therapeutics announced its participation in the 28th Annual H.C. Wainwright Global Investment Conference. The management team will deliver a corporate presentation and hold one-on-one meetings with investors.…more
$0.4990+3.92%vs prev close - 9.9Pre-market26.09.09 20:00
●●●●●●●● ●●●●● ●●●●●●
Actuate Therapeutics reported promising preclinical results showing synergistic anti-tumor activity when combining its lead candidate with RAS inhibitors in pancreatic cancer models. These findings are preliminary, and the company plans to further evaluate the combination in future clinical trials.…more
$0.4990+3.92%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report